Ranexa to lead Gilead's cardiology push
This article was originally published in Scrip
Executive Summary
Gilead Sciences is looking to Ranexa (ranolazine extended-release tablets) to succeed as the US biotech appears to have triumphed in its late bid for CV Therapeutics. Following months of confrontation between CV and Astellas on a takeover proposal at $16 per share, Gilead surfaced yesterday with a $20 per share bid that was accepted.